Cost Effectiveness and Budget Impact of Siponimod Compared to Interferon Beta-1a in the Treatment of Adult Patients with Secondary Progressive Multiple Sclerosis with Active Diseas...

por Schur, Nadine, Gudala, Kapil, Vudumula, Umakanth, Vadapalle, Sreelatha, Bhadhuri, Arjun, Casanova, Alain, Adlard, Nicholas, Schwenkglenks, Matthias
Publicado 2021

Comparing the long-term clinical and economic impact of ofatumumab versus dimethyl fumarate and glatiramer acetate in patients with relapsing multiple sclerosis: A cost-consequence...

por Koeditz, Dominik, Frensch, Juergen, Bierbaum, Martin, Ness, Nils-Henning, Ettle, Benjamin, Vudumula, Umakanth, Gudala, Kapil, Adlard, Nicholas, Tiwari, Santosh, Ziemssen, Tjalf
Publicado 2022

Cost–consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada

por Bhan, Virender, Clift, Fraser, Baharnoori, Moogeh, Thomas, Kimberly, Patel, Barkha P, Blanchette, François, Adlard, Nicholas, Vudumula, Umakanth, Gudala, Kapil, Dutta, Nikkita, Grima, Daniel, Mouallif, Soukaïna, Farhane, Fatine
Publicado 2023